BioVisioN AG receives United States Patent for Peptide-Biomarker Discovery and Identification Technology
Using mass spectrometry BioVisioN's Differential Peptide Display analyses virtual every peptide in clinical samples like blood or urine, offering sensitivities down to picograms per milliliter. Using bioinformatic software tools developed in-house, the quantitative comparison of hundreds of samples is possible, making the technology suitable for biomarker discovery within clinical trials. The comparison of samples from e.g. patients and healthy controls shows up quantitative differences in peptide content characteristic of the disease studied. This provides for the identification of new diagnostic markers or biomarkers and also therapeutic leads and targets.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!